ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

A zoster mRNA vaccine SYS6017

A development code.

Its studies are mostly in Herpes Zoster, led by CSPC Pharmaceutical Group.

Furthest: phase 2, since Dec 30, 20252 company-led studies, 2 open or runningNext primary completion: Mar 10, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
CSPC Pharmaceutical Group22 open or runningphase 2since Dec 30, 2025Apr 24, 2025Mar 10, 2027phase 2 · NCT07354659

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 24, 2025First study: phase 1 study in Herpes ZosterFirst studyNCT06954818 · 200 planned
  2. Dec 30, 2025Phase 2 study in Herpes ZosterPhase 2 reachedNCT07354659 · 800 planned

Ahead

  1. Mar 10, 2027Primary completion: phase 2 study in Herpes ZosterNCT07354659

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“A zoster mRNA vaccine SYS6017”name, by rule

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07354659Herpes Zoster2Not yet recruitingMar 10, 2027800
NCT06954818Herpes Zoster1Not yet recruitingDec 10, 2025200

How it is read

Names in the registry

  • “A zoster mRNA vaccine SYS6017”, 2 entries

Codes read as this program: SYS6017.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.